Latest Breaking News On - Nicholas chang - Page 3 : comparemela.com

Press release content from Business Wire. The AP news staff was not involved in its creation. Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics April 26, 2021 GMT BROOKLYN, N.Y. (BUSINESS WIRE) Apr 26, 2021 Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Matthew During, M.D., Ph.D. to the Company’s Scientific Advisory Board, effective April 26, 2021. Dr. During is a Harvard, MIT and Yale trained neuroscientist. He has served for 9 years as a member of the faculty of Yale as Professor of Neurosurgery, and as a Professor at Thomas Jefferson, Cornell, and Ohio State Universities. Dr. During was a pioneer in the use of viral vectors for neurological disorders, and was the first to carry out gene transfer into the brain of a human child. Dr. During

United statesEmrys bioBrooklyn immunotherapeuticsBioscience novellusNicholas changHowardj federoffBrooklyn immunotherapeuticThomas jeffersonBrooklyn immunotherapeutics incCompany scientific advisory boardMerlin pharmaceuticalsMatthew duringScientific advisory boardOhio statePrincipal investigatorNature medicine